Novartis Pharmaceuticals

This study looks at the long-term safety and effectiveness of the drug QCZ484 in people with high blood pressure. It is for patients who already completed a previous study with QCZ484. The goal is to monitor side effects and see how well the drug controls blood pressure over time…

This study looks at how children aged 6 to 17 with certain types of juvenile arthritis (enthesitis-related or psoriatic) are treated long-term with the drug secukinumab. Researchers will track whether the drug is continued, reduced, or stopped after the disease becomes inactive, …

This study looks at how safe and effective a gene therapy called onasemnogene abeparvovec (ITVISMA®) is for people with spinal muscular atrophy (SMA) in everyday medical practice. It will include 36 participants aged 2 and older who receive the treatment as part of their routine …

This study reviews the experience of 35 adults with complement 3 glomerulopathy (C3G), a rare kidney disease, who received the drug iptacopan through an early access program in Spain. Researchers will look at patient characteristics, lab results, and how the disease responds to t…

This study offers continued access to the cancer drug opnurasib for people with KRAS G12C-mutated lung or other solid tumors who are already benefiting from it in a Novartis-sponsored trial. About 40 participants will keep receiving opnurasib alone or with other treatments, while…

This study tests a drug called secukinumab in Chinese adults with moderate to severe hidradenitis suppurativa, a long-term skin condition causing painful lumps. The goal is to see if the drug reduces skin lesions and prevents flare-ups over 16 weeks. About 36 participants will re…

This early-phase study tests a new drug called IEV407, alone or with hormone therapy, in people with advanced HR+/HER2- breast cancer that has stopped responding to standard treatments. The main goals are to check safety and find the right dose. About 194 adults will take part ac…

This study follows 34 adults with moderate-to-severe hidradenitis suppurativa (HS) who are taking secukinumab as part of their regular care. Researchers want to see if this treatment can slow or prevent the growth of plaque in the heart's arteries over 12 months. Participants wil…

This study will test the drug Ilaris (canakinumab) in about 5 people with Schnitzler's syndrome, a rare condition that causes hives, fever, joint pain, and fatigue. The goal is to see if Ilaris can reduce or stop these symptoms. Participants will be followed for up to 48 weeks to…

This study is a safety check on the drug Fabhalta (iptacopan) for Korean adults with two rare diseases: paroxysmal nocturnal hemoglobinuria (PNH), a blood disorder, and C3 glomerulopathy (C3G), a kidney disease. Researchers will track side effects and lab results from up to 21 pa…

This study tests a new inhaler containing three medicines (QVM149) against a standard two-medicine inhaler in 304 teenagers aged 12 to 17 with asthma. The goal is to see if the triple combination improves lung function and symptom control over 52 weeks. Participants will be rando…

This study will check how safe and effective JAKAVI (ruxolitinib) is for patients with graft-versus-host disease (GVHD), a condition that can occur after a stem cell transplant. About 395 people will take part, and researchers will track infections and other side effects. The goa…

This study tests a new drug called ERW316, alone or with hormone therapy, in people with advanced breast cancer or other solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and check for side effects. About 217 adults will take part ac…

This study tests a new drug called asciminib, given with chemotherapy and later with another drug (blinatumomab), for children, teens, and young adults up to age 30 who have a certain type of leukemia (Ph+ or Ph-like ALL) that has come back or not responded to treatment. The goal…

This study will check if a newer blood pressure medicine called ARNi works better than standard treatments in adults with high blood pressure living in the United Arab Emirates. About 500 people will take either ARNi or a standard drug for up to 12 weeks. The main goal is to see …

This study tests an oral drug called atrasentan in 28 children aged 2 to 18 with IgA nephropathy, a kidney disease that can lead to kidney failure. The main goal is to see if the drug reduces protein in the urine, a sign of kidney damage, over 36 weeks. Participants will take the…

This early-stage study tests a new drug called DCY636 for safety and how the body processes it. It includes healthy volunteers and people with moderate to severe eczema (atopic dermatitis). The goal is to see if the drug is safe enough for further testing, not to cure the conditi…

This study will collect information from medical records of about 753 people with metastatic prostate cancer who have received a radioactive drug called lutetium-177. Researchers will use artificial intelligence to analyze treatment patterns, patient characteristics, and outcomes…

This study looks at medical records from Japan to see how well patients take two different cholesterol-lowering drugs (inclisiran and evolocumab) over 12 months. It will include about 3,600 adults with high cholesterol. The goal is to understand which treatment people are more li…

This study will follow about 6,000 Italian adults who are prescribed inclisiran, evolocumab, or alirocumab—medicines that lower cholesterol. Researchers want to see how consistently patients take these drugs over months and years in everyday life, not in a controlled clinic. The …

This study will review the medical records of 400 adults in Kuwait with chronic myeloid leukemia (CML) to learn about their backgrounds, health issues, and which treatments they received. The goal is to better understand how CML is managed in real-world settings and how other hea…

This study will follow 80 adults with IgA nephropathy who are prescribed iptacopan or atrasentan as part of their routine care. Researchers will collect data on patient characteristics, treatment patterns, and health outcomes over 24 months. The goal is to better understand how t…

This study looks at how eltrombopag is used in routine care for adults with primary immune thrombocytopenia (ITP) who have already tried steroids. Researchers will collect information from doctors in the US, UK, and Germany about treatment patterns and platelet responses. No new …

This study looks at how a cancer drug called pelabresib changes the way the body processes other drugs. It involves 24 adults with advanced cancers who have no standard treatment options. Participants will take pelabresib along with other medicines to measure drug levels in the b…

This study will review medical records of about 83 adults with C3 glomerulopathy (a rare kidney disease) who are taking the drug iptacopan. Researchers want to describe the patients' health history, lab results, and how their disease changes over 12 months of treatment. The goal …